Trial Profile
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Participants With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia; Renal failure
- Focus Therapeutic Use
- Sponsors Akebia Therapeutics
- 19 Sep 2016 Results published in Kidney International, the official journal of the International Society of Nephrology, as per an Akebia Therapeutics media release.
- 19 Sep 2016 Results published in an Akebia Therapeutics Media Release
- 28 Oct 2015 Results will be presented at the upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting, as per Akebia Therapeutics media release.